vs
PATHWARD FINANCIAL, INC.（CASH）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是PATHWARD FINANCIAL, INC.的2.0倍（$540.7M vs $276.3M），PATHWARD FINANCIAL, INC.净利率更高（26.4% vs -2.9%，领先29.3%），过去两年PATHWARD FINANCIAL, INC.的营收复合增速更高（21.0% vs -2.3%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
CASH vs ICUI — 直观对比
营收规模更大
ICUI
是对方的2.0倍
$276.3M
净利率更高
CASH
高出29.3%
-2.9%
两年增速更快
CASH
近两年复合增速
-2.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $540.7M |
| 净利润 | $72.9M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | — | 1.0% |
| 净利率 | 26.4% | -2.9% |
| 营收同比 | — | -14.1% |
| 净利润同比 | — | 34.0% |
| 每股收益（稀释后） | $3.35 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHICUI
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $540.7M | ||
| Q3 25 | $186.7M | $537.0M | ||
| Q2 25 | $195.8M | $548.9M | ||
| Q1 25 | $274.8M | $604.7M | ||
| Q4 24 | $182.6M | $629.8M | ||
| Q3 24 | $179.5M | $589.1M | ||
| Q2 24 | $188.6M | $596.5M |
净利润CASHICUI
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | $-15.7M | ||
| Q3 25 | $38.8M | $-3.4M | ||
| Q2 25 | $42.1M | $35.3M | ||
| Q1 25 | $75.0M | $-15.5M | ||
| Q4 24 | $30.0M | $-23.8M | ||
| Q3 24 | $33.5M | $-33.0M | ||
| Q2 24 | $44.9M | $-21.4M |
毛利率CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | 1.0% | ||
| Q3 25 | 25.9% | 2.6% | ||
| Q2 25 | 24.1% | 1.9% | ||
| Q1 25 | 33.2% | 2.1% | ||
| Q4 24 | 19.8% | 6.0% | ||
| Q3 24 | 20.9% | 1.4% | ||
| Q2 24 | 27.1% | 1.3% |
净利率CASHICUI
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | -2.9% | ||
| Q3 25 | 20.8% | -0.6% | ||
| Q2 25 | 21.5% | 6.4% | ||
| Q1 25 | 27.3% | -2.6% | ||
| Q4 24 | 16.4% | -3.8% | ||
| Q3 24 | 18.7% | -5.6% | ||
| Q2 24 | 23.8% | -3.6% |
每股收益（稀释后）CASHICUI
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $-0.63 | ||
| Q3 25 | $1.69 | $-0.14 | ||
| Q2 25 | $1.81 | $1.43 | ||
| Q1 25 | $3.14 | $-0.63 | ||
| Q4 24 | $1.23 | $-0.97 | ||
| Q3 24 | $1.34 | $-1.35 | ||
| Q2 24 | $1.78 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | — |
| 总债务越低越好 | $59.5M | — |
| 股东权益账面价值 | $850.7M | $2.1B |
| 总资产 | $7.1B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHICUI
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | — | ||
| Q3 25 | $120.6M | — | ||
| Q2 25 | $258.3M | — | ||
| Q1 25 | $254.2M | — | ||
| Q4 24 | $597.4M | $308.6M | ||
| Q3 24 | $158.3M | $312.5M | ||
| Q2 24 | $298.9M | $302.6M |
总债务CASHICUI
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
股东权益CASHICUI
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $2.1B | ||
| Q3 25 | $858.0M | $2.1B | ||
| Q2 25 | $819.0M | $2.1B | ||
| Q1 25 | $814.7M | $2.0B | ||
| Q4 24 | $758.3M | $2.0B | ||
| Q3 24 | $822.5M | $2.0B | ||
| Q2 24 | $748.4M | $2.0B |
总资产CASHICUI
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $4.1B | ||
| Q3 25 | $7.2B | $4.1B | ||
| Q2 25 | $7.2B | $4.1B | ||
| Q1 25 | $7.0B | $4.2B | ||
| Q4 24 | $7.6B | $4.2B | ||
| Q3 24 | $7.5B | $4.3B | ||
| Q2 24 | $7.5B | $4.3B |
负债/权益比CASHICUI
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $60.6M | ||
| Q3 25 | $303.7M | $56.7M | ||
| Q2 25 | $30.4M | $11.2M | ||
| Q1 25 | $188.3M | $51.3M | ||
| Q4 24 | $-71.7M | $40.2M | ||
| Q3 24 | $143.1M | $36.1M | ||
| Q2 24 | $113.2M | $82.0M |
自由现金流CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $36.0M | ||
| Q3 25 | $300.3M | $27.6M | ||
| Q2 25 | $27.7M | $-8.5M | ||
| Q1 25 | $184.7M | $36.7M | ||
| Q4 24 | $-73.8M | $16.1M | ||
| Q3 24 | $138.8M | $16.2M | ||
| Q2 24 | $111.0M | $62.5M |
自由现金流率CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | 6.6% | ||
| Q3 25 | 160.9% | 5.1% | ||
| Q2 25 | 14.1% | -1.5% | ||
| Q1 25 | 67.2% | 6.1% | ||
| Q4 24 | -40.4% | 2.6% | ||
| Q3 24 | 77.3% | 2.7% | ||
| Q2 24 | 58.8% | 10.5% |
资本支出强度CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 4.6% | ||
| Q3 25 | 1.8% | 5.4% | ||
| Q2 25 | 1.4% | 3.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.1% | 3.8% | ||
| Q3 24 | 2.4% | 3.4% | ||
| Q2 24 | 1.2% | 3.3% |
现金转化率CASHICUI
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | 0.32× | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
